Study Group: Statin Prescribers (US)(?)
Council Members in this Study Group: 56
Request a survey with this Study Group
Leading Experts in this Study Group
Clinical Director
NYU Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Clinical Professor of Medicine
University of California, Los Angeles
Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...
Charles Glueck, MDMedical Research Director of Cholesterol Center
Jewish Hospital
Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
It is important to understand that geographic placement of these clinics is important. I think these clinics will continue to pop up until the industry feels out exactly where the market is. We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...
I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.
The announcement the new trial comparing Lipitor to Crestor is interesting but not unexpected. It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.
Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming. But a closer looks shows that the results are realy quite impressive
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
- Contract Research Organization, Independent/Small
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Medical Director
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms